Brain cancer patient pays $8K a month for drug treatment - Action News
Home WebMail Saturday, November 23, 2024, 11:00 PM | Calgary | -12.1°C | Regions Advertise Login | Our platform is in maintenance mode. Some URLs may not be available. |
Calgary

Brain cancer patient pays $8K a month for drug treatment

A Calgary woman is paying thousand of dollars a month for the cancer drug Avastin a treatment that could prolong her life because it's not covered by the province for brain cancer.

Physicians asking province to cover drug that could prolong life of some patients

Jan Tollefson is paying thousands of dollars every month to be treated with the cancer drug Avastin, which the provincial government does not cover. (CBC)

A Calgarywoman with brain cancer is paying thousands of dollars a month for thedrug Avastin, becauseAlbertadoesn't cover it for her form of cancer.

"I was pretty shocked. I wasn't expecting my life to be cut off quite so abruptly," said JanTollefson, whowas diagnosed with glioblastoma, an aggressive form of brain cancer, three years ago.

She underwent radiation, chemotherapy and two surgeries, but her tumour returned after her second surgery in March.

Tollefson'soncologistprescribed Avastin.The drug targets a tumour's ability to form new blood vessels and grow.But it costs $8,000 a month, money the Calgary physician would prefer to leave to charity.

"I'm very uncomfortable with the thought of using my money to pay for it. I mean there's so many other things in the world that I'd much rather put my money into right now," Tollefsonsaid.

Her oncologist, Dr. Jay Easaw,has beenworking with the drug and is part of a group of physicians recommending that Avastinbe funded for a select group of brain cancer patientsas a second-line drug.

The physicians have approached the provincewith a request forblanket coverage.

"We're hopeful,you know really hopeful, because this is an expensive drug," said Easaw.

But Alberta Health says while Avastin has been approved for thetreatment of colorectal cancer, itisn't ready to approve the drug as a second-line treatment for cancers such as Tollefson'sglioblastoma.

"Decisions regarding drug coverage can be difficult and complex, andmust follow an evidence-based review process," Alberta Health said in a statement.

"The Joint Oncology Drug Review Committee, a national committee ofexperts and practitioners, recommended not listing Avastin for thetreatment of a glioblastomabecause of a lackof evidence over its effectiveness for thiscondition," it said.